The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Novo Nordisk ADR (NYSE: NVO) closed at $51.37 in the last session, down -1.31% from day before closing price of $52.05. In other words, the price has decreased by -$1.31 from its previous closing price. On the day, 9.34 million shares were traded. NVO stock price reached its highest trading level at $52.805 during the session, while it also had its lowest trading level at $51.191.
Ratios:
We take a closer look at NVO’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 58.05 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.22. For the most recent quarter (mrq), Quick Ratio is recorded 0.56 and its Current Ratio is at 0.78. In the meantime, Its Debt-to-Equity ratio is 0.59 whereas as Long-Term Debt/Eq ratio is at 0.52.
Morgan Stanley Downgraded its Equal-Weight to Underweight on September 29, 2025, while the target price for the stock was maintained at $47.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 30 ’25 when Novo Nordisk A/S bought 921,897 shares for $2.14 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVO now has a Market Capitalization of 232221114368 and an Enterprise Value of 308593000448. As of this moment, Novo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.15, and their Forward P/E ratio for the next fiscal year is 12.93. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.37. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.80 while its Price-to-Book (P/B) ratio in mrq is 8.63. Its current Enterprise Value per Revenue stands at 0.989 whereas that against EBITDA is 1.938.
Stock Price History:
The Beta on a monthly basis for NVO is 0.65, which has changed by -0.5411345 over the last 52 weeks, in comparison to a change of 0.20772064 over the same period for the S&P500. Over the past 52 weeks, NVO has reached a high of $113.76, while it has fallen to a 52-week low of $45.05. The 50-Day Moving Average of the stock is -8.89%, while the 200-Day Moving Average is calculated to be -23.89%.
Shares Statistics:
According to the various share statistics, NVO traded on average about 18.21M shares per day over the past 3-months and 10337630 shares per day over the past 10 days. A total of 3.37B shares are outstanding, with a floating share count of 3.37B. Insiders hold about 0.01% of the company’s shares, while institutions hold 9.17% stake in the company. Shares short for NVO as of 1760486400 were 26671758 with a Short Ratio of 1.46, compared to 1757894400 on 28735135. Therefore, it implies a Short% of Shares Outstanding of 26671758 and a Short% of Float of 0.7900001.
Dividends & Splits
The forward annual dividend rate for NVO is 1.73, which was 11.65 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.22382325. The stock’s 5-year Average Dividend Yield is 1.53. The current Payout Ratio is 35.93% for NVO, which recently paid a dividend on 2025-03-31 with an ex-dividend date of 2025-08-18. Stock splits for the company last occurred on 2023-09-20 when the company split stock in a 2:1 ratio.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 4.0 analysts currently analyzing and rating the stock of Novo Nordisk ADR (NVO).The consensus estimate for the next quarter is $6.16, with high estimates of $6.73 and low estimates of $5.71.
Analysts are recommending an EPS of between $25.08 and $22.28 for the fiscal current year, implying an average EPS of $23.52. EPS for the following year is $24.59, with 4.0 analysts recommending between $25.23 and $24.16.
Revenue Estimates
According to 11 analysts,. The current quarter’s revenue is expected to be $76.98B. It ranges from a high estimate of $79.65B to a low estimate of $75.1B. As of. The current estimate, Novo Nordisk ADR’s year-ago sales were $71.31BFor the next quarter, 11 analysts are estimating revenue of $80.81B. There is a high estimate of $82.69B for the next quarter, whereas the lowest estimate is $78.62B.
A total of 20 analysts have provided revenue estimates for NVO’s current fiscal year. The highest revenue estimate was $321.61B, while the lowest revenue estimate was $307.92B, resulting in an average revenue estimate of $313.61B. In the same quarter a year ago, actual revenue was $290.4BBased on 20 analysts’ estimates, the company’s revenue will be $328.32B in the next fiscal year. The high estimate is $346.22B and the low estimate is $307.57B.
